Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study
Dapagliflozin exerted robust cardioprotective effects against PMI/4aMI in patients with T2DM and CCS undergoing PCI, particularly among patients in high-risk subgroups, but it did not significantly reduce the risk of CI-AKI. These findings support the peri-PCI use of dapagliflozin to mitigate cardiac risk while highlighting the need for further research to elucidate its renal effects in this population.
Authors
- Deping Liu (ORCID: https://orcid.org/0000-0001-5887-4120)
- Chi Zhang (ORCID: https://orcid.org/0000-0002-5423-4182)
- Zinan Zhao (ORCID: https://orcid.org/0000-0002-3797-8999)
- Ming Lan (ORCID: https://orcid.org/0000-0001-8445-8243)
- Hui Li (ORCID: https://orcid.org/0000-0002-4611-7808)
- Yuwei Li (ORCID: https://orcid.org/0000-0002-5488-242X)
- Tianqi Zhang (ORCID: https://orcid.org/0000-0002-2940-6843)
- Hu Ai (ORCID: https://orcid.org/0000-0001-6502-890X)
- Naixin Zheng (ORCID: https://orcid.org/0000-0002-9201-9299)
- Ni Zhang (ORCID: https://orcid.org/0000-0002-4563-6307)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1186/s12933-025-02678-9
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18